AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Highlights
- Castle Biosciences anticipates 2024 revenue between $320M-$330M, reflecting 50% growth YoY.
- Total test reports for 2024 increased 36%, reaching 96,071 tests.
- Strong cash position with $293M in cash and investments.
Castle Biosciences (NASDAQ:CSTL) has announced preliminary unaudited financial results for the fourth quarter and full-year 2024, reporting significant growth across key metrics. The company expects to meet or exceed the high end of its revenue guidance for 2024, projecting between $320 million and $330 million, which marks a substantial year-over-year increase of at least 50%. This growth is driven by strong demand for its diagnostic tests, as evidenced by a 36% increase in the total number of test reports delivered, reaching 96,071 for the year.
Fourth Quarter and Full-Year 2024 Performance:
- Test Report Growth: In Q4 2024, Castle Biosciences delivered 24,071 test reports, a 19% increase compared to the same period in 2023. This increase highlights the company's continued momentum in expanding its test offerings and customer base.
- Notable Test Performance: The company's TissueCypher Barrett's Esophagus test saw impressive growth, with reports increasing by 94% year-over-year. This surge is indicative of heightened awareness and demand for diagnostic tests related to esophageal cancer risk. Similarly, DecisionDx-SCC, which aids in assessing cutaneous squamous cell carcinoma, grew by 22%. Both tests are contributing to the company’s expanding portfolio and overall success.
- Declines in Specific Tests: On the downside, the MyPath Melanoma and IDgenetix tests experienced declines in Q4, with test reports decreasing by 14% and 5%, respectively. Additionally, the growth of other tests such as DecisionDx-UM (Uveal Melanoma) and DecisionDx-Melanoma was minimal, with only a 1% increase in both categories. This suggests some challenges in these specific areas, which may need attention moving forward.
- Financial Position: As of year-end 2024, Castle Biosciences maintains a strong financial position, with approximately $293 million in combined cash, cash equivalents, and marketable investment securities. This solid cash balance positions the company well to invest in future growth opportunities and navigate potential industry challenges.
Medicare Non-Coverage Determination:
In a setback for the company, on January 9, 2025, Novitas, a Medicare Administrative Contractor, issued a non-coverage determination for the DecisionDx-SCC test. This decision could impact the adoption and reimbursement for the test, potentially limiting its use among Medicare patients. Castle Biosciences will need to assess the broader implications of this ruling and explore alternative strategies for maintaining growth in this segment.
